Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Baricitinib for Reduction of HIV - CNS — Stella

Home/Human Immunodeficiency Virus/Baricitinib for Reduction of HIV - CNS

View on ClinicalTrials.gov

Recruiting

Back to Human Immunodeficiency Virus trials

Baricitinib for Reduction of HIV - CNS

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Grady Memorial Hospital, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

Key details

Phase

Safety & dosing

Sponsor

William Tyor

Collaborators

National Institute of Mental Health (NIMH)

Enrollment target

~95 participants

Started

May 2023

Primary completion

January 2028

Age range

18 Years – 65 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.